Response of Mucinous Breast Carcinoma to Neoadjuvant Chemotherapy
Author Information
Author(s): Berkay KILIÇ, Burak İLHAN
Primary Institution: İstanbul University
Hypothesis
The study aimed to define the response of mucinous breast carcinomas (MBCs) to neoadjuvant chemotherapy (NAC).
Conclusion
NAC is not sufficiently effective in reducing the need for mastectomy or preventing axillary clearance in MBCs, and it does not significantly benefit survival.
Supporting Evidence
- NAC was used in 11.4% of patients, but did not achieve clinical or pathological complete response.
- Five-year disease-free survival (DFS) and overall survival (OS) rates were 92.9% and 95.7%, respectively.
- Patients receiving NAC had higher tumor sizes and clinically positive axilla compared to those receiving adjuvant treatment.
Takeaway
This study looked at how a specific type of breast cancer responds to a treatment called neoadjuvant chemotherapy, and it found that this treatment doesn't really help patients avoid surgery or live longer.
Methodology
A review of demographic, clinicopathologic characteristics, management, and follow-up data of 70 patients diagnosed with MBC between May 2010 and December 2020.
Limitations
The small number of patients receiving NAC limits the generalizability of the findings.
Participant Demographics
Median age was 52.9 years, with a range of 32 to 87 years; 92.9% of tumors were classified as luminal.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website